Document is current
Any future updates will be listed below
-
Authors
Triplett, Kathleen D.
Pokhrel, Srijana
Castleman, Moriah J. https://orcid.org/0000-0001-7219-5044
Daly, Seth M.
Elmore, Bradley O.
Joyner, Jason A.
Sharma, Geetanjali
Herbert, Guy
Campen, Matthew J.
Hathaway, Helen J.
Prossnitz, Eric R. https://orcid.org/0000-0001-9190-8302
Hall, Pamela R. https://orcid.org/0000-0003-2367-3382
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (ES014639)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA163890)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA194496)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI128159)
- License Information
-
More Information
Article History
Received: 23 September 2018
Accepted: 7 December 2018
First Online: 4 February 2019
Competing Interests
: E.R.P. is an inventor on U.S. patents 7,875,721 and 8,487,100 for GPER-selective ligands and imaging agents and applications for the therapeutic use of compounds targeting GPER. P.R.H., H.J.H. and E.R.P. are inventors on U.S. patent application 16/067,721 for therapeutic use of compounds targeting GPER for treatment of bacterial infections.
